ClinicalTrials.gg
Status unknownNCT01360879FIBROELASTUpdated May 26, 2011

Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease

An observational study in Chronic Hepatitis B and Chronic Hepatitis C, sponsored by Kindai University. Status unknown at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-05-26.

Sponsored by Kindai University · Observational

How we know

The sponsor has not verified this record recently (last verified Aug 2010), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Time perspective
Prospective
Enrollment
500
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Hepatitis B, Chronic with a site in Japan — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · Japan.

Started
2010
with 1 other
Observational
2 of 19
none open now
Registered
3rd of 19
by date
Lead sponsor
2 of 19
Kindai University

Among the 19 studies in Hepatitis B, Chronic with a site in Japan, this one is one of 2 that started in 2010, is one of 2 observational ones, and was the 3rd registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 19 studies in Hepatitis B, Chronic with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Hepatitis B, Chronic with a site in Japan, or all of them as a file.
02

Study summary

This is a multi-center cross-sectional study in which the Real-time Tissue Elastography® measurements will be collected prospectively from patients with chronic hepatitis B or C virus presenting for liver biopsy.

Read the detailed description

The aim of this study is to validate the diagnostic value of Real-time Tissue Elastography® by comparison with liver histology, serum marker or FibroScan® in chronic hepatitis B or C patients.Real-time Tissue Elastography®, biopsy and serum maker are performed.

If in the hospital they can perform FibroScan®, FobroScan® also be performed. The subjects must be scheduled for liver biopsy either prior to treatment (treatment naïve) or, if previously treated, they must have been off treatment for at least six months. The time between the Real-time Tissue Elastography® , biopsy, blood sampling and FiroScan® must not exceed four weeks.

03

Conditions studied

  • Chronic Hepatitis B
  • Chronic Hepatitis C

Keywords

  • Hepatitis B virus
  • Hepatitis C virus
  • Chronic hepatitis
  • Liver cirrhosis
  • Liver stiffness
  • Liver fibrosis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects with chronic hepatitis B or C, undergoing a liver biopsy as the standard of care for their disease, will be eligible for the study. Subjects with other infectious viral diseases or chronic liver disease are excluded for study enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female and at least 20 years of age
  • Chronic or Chronic
  • Subject is willing to fast for 8 hours prior to each study visit

Exclusion criteria

Exclusion Criteria:

  • History of alcohol abuse (alcohol intake > 20g/day)
  • Evidence or history of chronic hepatitis not caused by or
  • During 6 months before registration to this trial has completed, nucleic acid analogue preparations or interferon therapy was performed.
  • Pregnant or lactating patients
  • of liver or liver resection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Time perspective
Prospective
Enrollment
500 participants (estimated)
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Correlative evaluation with liver fibrosis by Real-time Tissue Elastography® and histological diagnosis

    To evaluate the correlation between Real-time Tissue Elastography® index and histological diagnosis (the gold standard for liver fibrosis), we calculate sensitivity and specificity, ROC curves. Sensitivity, specificity and ROC curves obtained under below stiations: 1. liver fibrosis index diagnose of histological diagnosis F4 2. liver fibrosis index diagnose of histological diagnosis F3 or greater 3. liver fibrosis index diagnose of histological diagnosis F2 or greater

    Time frame: one year

Secondary outcomes

  1. Correlative evaluation with liver fibrosis by Real-time Tissue Elastography® and serum maker

    To evaluate the correlation between Real-time Tissue Elastography® index and serum markers of hepatic fibrosis, we estimate Pearson correlation coefficient of each request.

    Time frame: one year

  2. Correlative evaluation with liver fibrosis by Real-time Tissue Elastography® and FibroScan®

    To evaluate the correlation between Real-time Tissue Elastography® index and FibroScan® index, we estimate Pearson correlation coefficient of each request.

    Time frame: one year

07

Study locations

1 of 1 sites recruiting
  • Kinki University Faculty of Medicine
    Osaka-sayama, Osaka 589-8511, Japan
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Aug 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2011
First posted
May 26, 2011
Start
Sep 2010
Primary completionEst.
Aug 2013
CompletionEst.
Sep 2013
Last update
May 26, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01360879
Lead sponsor
Kindai University
First posted
May 26, 2011
Start date
Sep 2010
Primary completion
Aug 2013 (estimated)
Completion
Sep 2013 (estimated)
Last update
May 26, 2011

Study contacts

Norihisa Yada, M.D.
Contact
yada@med.kindai.ac.jp
+81-72-366-0221 ext. 3525
Kazuomi Ueshima, M.D.
Contact
kaz-ues@med.kindai.ac.jp
+81-72-366-0221 ext. 3525
Masatoshi Kudo, Professor
study chair · Kinki University Faculty of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion